PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry

Oxford, UK, 18 November 2021

PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, during an event last week at Seoul Yeouido SHIC tower, Seoul, South Korea.

Through this MOU, PharmaVentures and Shinhan Investment Corp intend to collaborate closely to provide a much broader range of capabilities and services to both Korean biotech companies and global biopharma companies looking at the Korean biotech opportunity. This will allow better access for the pharma and biotech industry to the financial services provided by Shinhan Investment Corp and the corporate advisory services provided by PharmaVentures who have reach into the global markets.  The collaboration intends to give Korean companies better access to global markets, and for international companies to gain greater access to the Korean bio industry and its capital markets.

Adrian Dawkes, Managing Director at PharmaVentures said “We have been assisting many Korean biotech companies over the last 5 years and with our new collaboration with Shinhan Investment Corp we will be able to assist even more companies and bring the technology innovations of the Korean biotech sector to new audiences globally”.

SHIC GIB Group Head Keunsoo Chung said, “Starting with this MOU, SHIC will assist bio ventures to successfully enter the capital market and provide differentiated investment banking services to mid-to-large size pharma to succeed in global biopharma industry. This MOU provides groundwork to improve the quality of strategic consulting and financial services for Korean bio/healthcare companies to innovate the IPO and M&A domains”.

Fintan Walton, Founder and CEO of PharmaVentures, said PharmaVentures has a long and strong history in supporting our clients in their deal making activities. Our specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms. We have the expertise to connect the Korean and Western Biopharma industries and vice versa, enabling them to collaborate through licensing and M&A deals.”

South Korea is recognised as one of the leading nations for innovation, and Western pharmas are increasingly turning their attention to the rapidly expanding biotech sector there.  

Examples of PharmaVentures work with Korean clients include:

  • Advisor to IntoCell throughout the initiation, negotiation, and execution of this multi-target collaboration agreement with Cellectar read more
  • Advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4 read more
  • Valuation advisor to Yuhan Corporation on its licensing of Lazertinib for NSCLC to Janssen read more

– Ends –

For further information, please contact:

Adrian Dawkes​
Managing Director
Phone: +44 (0) 7931 428487
adrian@pharmaventures.com

Luke Lee​
Associate
Phone: +44 (0) 7859 885177
luke@pharmaventures.com

Jessie You
Associate
Phone: +44 (0)7387 101283
jessie@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

Shinhan Investment Corporation

Shinhan Investment Corp (SHIC) is one of Korea’s leading securities brokerage and investment banking houses. Through merger with Shinhan Securities, SHIC set a solid platform to become an investment powerhouse with excellence in financial service advisory and execution. SHIC’s long-term objectives and determination lie in pursuing high capital efficiency and business diversification, achieving industry’s top client and employee satisfaction, sustaining profitable growth in the long-term and most importantly creating higher value for their shareholders.

This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, at Seoul Yeouido SHIC tower, Seoul, South Korea.

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

Oxford, UK, 15 October 2021

PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.

This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio.

Steve Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell with forming another research and development collaboration, and we look forward to seeing the results of combining IntoCell’s OHPAS linker and PMT payload technologies with Ab Studio’s innovative approach to antibody discovery.

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures has advised and supported IntoCell through the course of their discussion with Ab Studio for the research collaboration agreement. PharmaVentures hopes to continue the strong relationship with IntoCell in advising on their business development and licensing activities with our special insight accumulated over many years of supporting Korean biotech companies.”

– Ends –

For further information on Intocell’s opportunities, contact:

Stephen Waterman
Managing Director
PharmaVentures Ltd
stephen@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

About IntoCell, the OHPAS linker and PMT technology

IntoCell has developed a state-of-the-art linker technology comprising of a novel self-immolative group based on Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OPHAS linker was designed to accommodate a wide variety of functional groups and triggering groups. The OHPAS Linker can be triggered by methods that include enzymes (i.e., lysosomal), light, and pH. The resulting ADCs has been shown to be highly stable and have very fast payloads release profiles.

IntoCell has devised another ADC platform technology called Payload Modification Technology (PMT) in which temporary Modifying Group (MG) has been incorporated into traditional payloads. PMT has shown to improve therapeutic index of ADC with significant reduction of normal cell’s uptake, resulting in normal cells being minimally affected.

By utilizing PMT and OHPAS linker technology, IntoCell has successfully delivered a preclinical candidate in the B7-H3 ADC program. ITC-6146RO is the lead candidate that shows high and long-lived potency in a variety of murine xenograft and PDX models with good safety. IND-enabling studies of ITC-6146RO are planned in 2022.

For more information, please visit http://www.intocell.co.kr

PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar

Oxford, UK, 15 July 2021

PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar.

This follows the announcement that Cellectar and Intocell have expanded their collaboration using Intocell’s proprietary OHPAS linker and payload technologies to develop novel phospholipid ether drug conjugates (PDCs).

Steve Waterman, Managing Director at PharmaVentures, said “The collaboration with Cellectar has produced exciting preclinical results with multiple payloads, and the decision to advance these programmes into Investigational New Drug (IND) enabling studies is very encouraging.

We are looking forward to continuing to support Intocell with partnering of its Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker and its novel payloads that promise a wider therapeutic index over existing technology. Equally exciting is the progress with its pipeline of proprietary antibody drug conjugates (ADCs), the most advanced of which is its B7-H3 ADC. ”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures is pleased to have advised Intocell throughout the initiation, negotiation, and execution of this multi-target collaboration agreement with Cellectar. PharmaVentures has a long and strong history in supporting our clients in their deal making activities due to our considerable transactional insight of the healthcare sector.  Furthermore, our specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms.”

– Ends –

For further information on Intocell’s opportunities, contact:

Stephen Waterman
Managing Director
PharmaVentures Ltd
stephen@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

About IntoCell and the OHPAS linker 

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. IntoCell has developed a novel self-immolative Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker that works with a wide variety of functional groups, triggering groups, and both phenolic and non-phenolic payloads. The resulting ADCs have proven to be highly stable in chemical and biological environments and have demonstrated excellent potencies in-vitro and in-vivo. IntoCell has also developed proprietary benzodiazepine dimers and modified duocarmycinoids that show high potency with improved safety in preclinical models. IntoCell has created an OHPAS Linker-toxin Library containing a variety of toxins that can be optimized for the fast delivery of a pre-clinical candidate in novel ADC programs.

Using its novel chemistries, IntoCell is developing a pipeline of proprietary ADCs that includes a B7-H3 programme which is demonstrating excellent preclinical data.

For more information, please visit http://www.intocell.co.kr

PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM

Oxford, UK, 29 June 2021

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM on June 22nd.

Adrian Dawkes, Managing Director at PharmaVentures, said: “Through our expert knowledge across the medical device sector, and in particular the wound care market, we were pleased to be able to provide an independent expert assessment of Spectral’s DeepView® Wound Imaging System with respect to their Initial Public Offering (IPO) on AIM.”

Fintan Walton, Chief Executive of PharmaVentures, said: “Providing independent expert commercial and technical insight in healthcare is a key component in contributing to understanding investment opportunities including IPOs and other transactions. PharmaVentures has a long and strong history in providing valuable commercial insight to our clients because of our deep commercial knowledge of the healthcare sector.”

Marc Dudek, Director of Business and Corporate Development at Spectral MD, said: “Spectral MD is delighted to IPO on the AIM market. This funding will be used to support further development of our diabetic foot ulcer application and to initiate our expansion into the UK and EU markets. We believe our differentiated technology has the potential to improve the standard of care for victims suffering from burn wounds and diabetic foot ulcers.”

PharmaVentures has a strong track record for writing Independent Expert Reports for companies listing on public markets such as AIM. These reports assist both the lay person and those with industry experience to understand how the company’s particular technology is positioned against competitors, where it brings technical or clinical benefits and how that relates to commercialisation.

– Ends –

For further information, contact:

Lisa Holloway
Senior Marketing Manager
PharmaVentures Ltd
+44 (0) 1865 332 700
enquiries@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 29 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

About Spectral MD                                                        

Spectral MD develops technology using predictive analytics and AI algorithms to help clinicians make more accurate and faster treatment decisions. There are no diagnostic imaging devices that provide clinicians with an objective and immediate assessment of a wound’s healing potential.

Spectral MD’s DeepView® Technology provides an informed solution for clinicians and allows for a clear picture of the wound to be established prior to treatment or other interventions.

www.spectralmd.com

NOTE: This Press release is issued by PharmaVentures Capital Limited which is authorised and regulated by the Financial Conduct Authority (FCA), and is for information purposes only. This communication does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

Oxford, UK, 03 March 2021

PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH.

ERA Consulting is a leading strategic product development and regulatory consulting group serving the global biopharmaceutical industry. For nearly 30 years, the company has provided services at all stages of product development, from conception to registration and beyond, and has enjoyed considerable success completing projects on hundreds of products for a wide range of top international clients.

“This transaction highlights our track record in supporting the sale of specialist pharmaceutical clinical services companies in the pharmaceutical industry,” said Dr Fintan Walton, CEO and Founder of PharmaVentures. “Our decades of experience in M&A, together with our detailed knowledge of the pharmaceutical clinical services industry which includes the global regulatory affairs outsourcing market, enabled us to deliver the optimal deal for the owner of ERA Consulting Group.”

Sabine Husmann-Holloway, Co-Founder & CEO of ERA Consulting Group, said, “I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company. They have a comprehensive understanding of our business and helped me identify the ideal partner that shared our strategic vision. The Company’s strong market position was effectively communicated to the potential buyer. I truly value the professional advice and the expert guidance made through every step of the process which enabled us to close the transaction to the satisfaction of all stakeholders.”

Mark Andrews, Managing Director at PharmaVentures said, “In 2020, the global regulatory affairs market was valued at US$ 6.3 billion and is expected to achieve a CAGR of 11.9% over the forecast period between 2021-20281. This particular sector of the Life Sciences market has been experiencing a high degree of consolidation, a trend that is set to continue. This makes it an ideal time for owners of businesses in the pharmaceutical services sector to talk to us about their future plans.”

This M&A deal follows PharmaVentures’ continued success in advising both shareholders in the pharmaceutical services sector on the sale of their businesses as well as major pharmaceutical companies in the divestment of their manufacturing operations to key players in the pharmaceutical services sector.

Source:1 Grand View Research https://www.grandviewresearch.com/industry-analysis/regulatory-affairs-outsourcing-market

– Ends –

For further information, contact:

Lisa Holloway
Senior Marketing Manager
PharmaVentures Ltd
+44 (0) 1865 332 700
enquiries@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 28 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit www.pharmaventures.com.

PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor

Oxford, UK, 24th November 2020

PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4.

GPCR has signed an exclusive agreement with TaiGen Biotechnology Company Ltd (TaiGen) for the development of Burixafor for worldwide markets.

GPCR Therapeutics is a leading Korean biotechnology company, a world leader in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets. CXCR4 antagonism is an accepted avenue for cancer therapy and GPCR Therapeutics has significant experience and knowledge that will enable the development of Burixafor in the oncology field.

Dongseung Seen, CEO of GPCR Therapeutics, said, “This collaboration with TaiGen, which is a leading biotech company engaged in innovative molecular-based platforms with strong R&D capabilities, will lead to a long-term strategic and productive partnership. Further, it is our goal that our work together will position us to be a pre-eminent developer of anti-CXCR4 oncology drugs.”

Summer Park, Senior Business Development Director, PharmaVentures said: “In the past decade we’ve seen more exciting innovative technologies coming out of Korea. We are proud to have supported GPCR in this process which has enabled the company to further its aim of developing novel and effective anti-cancer therapies.”

Adrian Dawkes, Managing Director at PharmaVentures, added “South Korea is forging ahead with the internationalisation of its innovative biotechnology sector and we, at PharmVentures, are pleased to be able to bring our knowledge of both Korean and Western cultures to support our Korean clients with their global transactions.”

This partnering deal follows PharmaVentures’ continued successes in working with Korean companies to enable them to expand further into the international market.

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Ltd undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.

Services include:

  • Pharma M&A (divestments, pharma mergers, acquisitions and strategic transactions)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, fundraising & expert testimonies)
  • Licensing (in and out licensing)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
  • Private Placement Fundraising

PharmaVentures is based in Oxford, UK, employs over 20 professionals and has associates in N. America, Latin America, Asia-Pacific.

For further information, contact:

Dr Fintan Walton

CEO

PharmaVentures Ltd

+44 1865 332 700

enquiries@pharmaventures.com